Partners
Ulysses Neuroscience
Innovation Partner
Ulysses Neuroscience Ltd. is a Private R&D Organization having a more collaborative way of working with pharmaceutical companies. Our translational research investigates the molecular mechanisms leading to the synaptic pathology and neuroinflammatory events which may anticipate development of psychiatric and neurodegenerative disorders.
NSA
Exhibition Partner
Proprietary MultiBrain® technology powers NSA’s simultaneous sectioning, and expertly guided staining, of up to 40 neuronal tissues in one MultiBrain® block, achieving uniform processing across all 40 tissues. Implementing NSA’s Large Format™ technology enables sectioning and staining of intact human brain hemispheres and yields comprehensive, uninterrupted vantage and analysis of the ultimate target. Coupling these mass production technologies with cutting-edge digital image capture and hosting, along with contemporary analysis tools increasingly powered by AI, rapidly produces rich data, and dramatically reduces R&D times.
Genomenon
Exhibition Partner
Genomenon is a genomic health IT company that keeps pace with the constant advancements made in genomics and connects that research to patient DNA to help diagnose and treat patients with rare genetic diseases and cancer. Mastermind Genomic Landscapes inform pharmaceutical companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence. Genomenon was named Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan
Transpharmation
Event Partner
Transpharmation is a preclinical CRO led by scientists. Established in 2010, Transpharmation has built on the international reputation and CNS drug discovery expertise of the founders. Transpharmation is recognised globally, and clients benefit from decades of experience in translational biology across multiple neuroscience preclinical services including EEG, cognition, epilepsy, pain, neurodegeneration and anxiety/mood disorders (including treatment-resistant depression and schizophrenia), together with a biomarker platform and human tissue capabilities. At Transpharmation, science will always remain our passion.